EC Statement: Competition - Commission fines AstraZeneca €60 million for misusing patent system to delay market entry of competing generic drugs
****************************************The European Commission has fined Anglo-Swedish group AstraZeneca €60 million for misusing the patent system and the procedures for marketing pharmaceuticals to block or delay market entry for generic competitors to...To view the full article, register now.
Already a subscriber? Click here to view full article